Browsing by Author "Podhajski, Przemysław"

Now showing items 1-2 of 2

    • A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study 

      Kubica, Jacek; Adamski, Piotr; Niezgoda, Piotr; Kubica, Aldona; Podhajski, Przemysław; Barańska, Malwina; Umińska, Julia M.; Pietrzykowski, Łukasz; Ostrowska, Małgorzata; Siller-Matula, Jolanta M.; Badarienė, Jolita; Bartuś, Stanisław; Budaj, Andrzej; Dobrzycki, Sławomir; Fidor, Łukasz; Gąsior, Mariusz; Gessek, Jacek; Gierlotka, Marek; Gil, Robert; Gorący, Jarosław; Grzelakowski, Paweł; Hajdukiewicz, Tomasz; Jaguszewski, Miłosz; Janion, Marianna; Kasprzak, Jarosław; Kern, Adam; Klecha, Artur; Kleinrok, Andrzej; Kochman, Wacław; Krakowiak, Bartosz; Legutko, Jacek; Lesiak, Maciej; Nosal, Marcin; Piotrowski, Grzegorz; Przybylski, Andrzej; Roleder, Tomasz; Skonieczny, Grzegorz; Sobieszek, Grzegorz; Tycińska, Agnieszka; Wojciechowski, Dariusz; Wojakowski, Wojciech; Wójcik, Jarosław; Zielińska, Marzenna; Żurakowski, Aleksander; Specchia, Giuseppe; Gorog, Diana A.; Navarese, Eliano P. (2021-06-02)
      The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment ...

    • PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection 

      Navarese, Eliano P.; Podhajski, Przemysław; Gurbel, Paul A.; Grzelakowska, Klaudyna; Ruscio, Eleonora; Tantry, Udaya; Magielski, Przemysław; Kubica, Aldona; Niezgoda, Piotr; Adamski, Piotr; Junik, Roman; Przybylski, Grzegorz; Pilaczyńska-Cemel, Marta; Rupji, Manali; Specchia, Giuseppe; Pinkas, Jarosław; Gajda, Robert; Gorog, Diana A.; Andreotti, Felicita; Kubica, Jacek (2023-01-24)
      Background The intensity of inflammation during COVID-19 is related to adverse outcomes. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in low-density lipoprotein receptor homeostasis, with potential ...